Below are the financial statements of Kymera Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Collaboration revenue | 47.07a | 78.59a | 46.83a |
| Operating expenses | — | — | — |
| Research and development | -240.25a | -189.08a | -164.25a |
| General and administrative | -63.53a | -55.04a | -43.83a |
| Impairment of long-lived assets | -4.93a | 0a | 0a |
| Total operating expenses | -308.71a | -244.12a | -208.08a |
| Loss from operations | -261.64a | -165.53a | -161.26a |
| Other income (expense) | — | — | — |
| Interest and other income | 38.03a | 18.76a | 6.62a |
| Interest and other expense | -0.25a | -0.2a | -0.18a |
| Total other income | 37.78a | 18.57a | 6.45a |
| Net loss | -223.86a | -146.96a | -154.81a |
| Reconciliation of net loss to net loss attributable to common stockholders | — | — | — |
| Net loss | -223.86a | -146.96a | -154.81a |
| Net loss attributable to common stockholders | -223.86a | -146.96a | -154.81a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Kymera Therapeutics’s data sources below and access millions more through our Disclosure Search.